Metabolic tumor volume predicts outcome in advanced stage follicular lymphoma patients from the Relevance trial.
Fiche publication
Date publication
octobre 2023
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre
Tous les auteurs :
Cottereau AS, Rebaud L, Trotman J, Feugier P, Nastoupil LJ, Bachy E, Flinn IW, Haioun C, Ysebaert L, Bartlett NL, Tilly H, Casasnovas O, Ricci R, Portugues C, Buvat I, Meignan M, Morschhauser F
Lien Pubmed
Résumé
We investigated the prognostic value of baseline PET parameters for patients with treatment-naïve follicular lymphoma (FL) in the phase 3 RELEVANCE trial, comparing the immunomodulatory combination of lenalidomide and rituximab (R) vs R-chemotherapy (R-chemo), with both regimens followed by R maintenance therapy.
Mots clés
Follicular lymphoma, Maintenance therapy, Metabolic tumor volume, PET/CT, Prognostication
Référence
Ann Oncol. 2023 10 26;: